The Letter of Intent is an investigator's declaration of interest in conducting a Phase II trial with a specific investigational drug in a particular disease. Approval of the LOI by CTEP commits an investigator to submit a protocol within a specified timeframe.
SWOG-coordinated “Master Protocol” (S1400). A Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer. This screening and multi-sub-study randomized phase II/III trial – and umbrella trial – will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid.